Literature DB >> 28716551

Application of human induced pluripotent stem cells to model fibrodysplasia ossificans progressiva.

Emilie Barruet1, Edward C Hsiao2.   

Abstract

Fibrodysplasia ossificans progressiva (FOP) is a genetic condition characterized by massive heterotopic ossification. FOP patients have mutations in the Activin A type I receptor (ACVR1), a bone morphogenetic protein (BMP) receptor. FOP is a progressive and debilitating disease characterized by bone formation flares that often occur after trauma. Since it is often difficult or impossible to obtain large amounts of tissue from human donors due to the risks of inciting more heterotopic bone formation, human induced pluripotent stem cells (hiPSCs) provide an attractive source for establishing in vitro disease models and for applications in drug screening. hiPSCs have the ability to self-renew, allowing researchers to obtain large amounts of starting material. hiPSCs also have the potential to differentiate into any cell type in the body. In this review, we discuss how the application of hiPSC technology to studying FOP has changed our perspectives on FOP disease pathogenesis. We also consider ongoing challenges and emerging opportunities for the use of human iPSCs in drug discovery and regenerative medicine.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Activin A type I receptor; Fibrodysplasia ossificans progressiva; Human disease models; Human induced pluripotent stem cells

Mesh:

Substances:

Year:  2017        PMID: 28716551      PMCID: PMC5767535          DOI: 10.1016/j.bone.2017.07.003

Source DB:  PubMed          Journal:  Bone        ISSN: 1873-2763            Impact factor:   4.398


  72 in total

1.  Generation and validation of PAX7 reporter lines from human iPS cells using CRISPR/Cas9 technology.

Authors:  Jianbo Wu; Samuel D Hunt; Haipeng Xue; Ying Liu; Radbod Darabi
Journal:  Stem Cell Res       Date:  2016-01-13       Impact factor: 2.020

2.  Dysregulation of the BMP-p38 MAPK signaling pathway in cells from patients with fibrodysplasia ossificans progressiva (FOP).

Authors:  Jennifer L Fiori; Paul C Billings; Lourdes Serrano de la Peña; Frederick S Kaplan; Eileen M Shore
Journal:  J Bone Miner Res       Date:  2006-06       Impact factor: 6.741

3.  Hematopoietic differentiation and production of mature myeloid cells from human pluripotent stem cells.

Authors:  Kyung-Dal Choi; Maxim Vodyanik; Igor I Slukvin
Journal:  Nat Protoc       Date:  2011-02-17       Impact factor: 13.491

4.  Alk2 regulates early chondrogenic fate in fibrodysplasia ossificans progressiva heterotopic endochondral ossification.

Authors:  Andria L Culbert; Salin A Chakkalakal; Edwin G Theosmy; Tracy A Brennan; Frederick S Kaplan; Eileen M Shore
Journal:  Stem Cells       Date:  2014-05       Impact factor: 6.277

5.  Limited gene expression variation in human embryonic stem cell and induced pluripotent stem cell-derived endothelial cells.

Authors:  Mark P White; Abdul J Rufaihah; Lei Liu; Yohannes T Ghebremariam; Kathryn N Ivey; John P Cooke; Deepak Srivastava
Journal:  Stem Cells       Date:  2013-01       Impact factor: 6.277

6.  Transplantation of genetically corrected human iPSC-derived progenitors in mice with limb-girdle muscular dystrophy.

Authors:  Francesco Saverio Tedesco; Mattia F M Gerli; Laura Perani; Sara Benedetti; Federica Ungaro; Marco Cassano; Stefania Antonini; Enrico Tagliafico; Valentina Artusi; Emanuela Longa; Rossana Tonlorenzi; Martina Ragazzi; Giorgia Calderazzi; Hidetoshi Hoshiya; Ornella Cappellari; Marina Mora; Benedikt Schoser; Peter Schneiderat; Mitsuo Oshimura; Roberto Bottinelli; Maurilio Sampaolesi; Yvan Torrente; Vania Broccoli; Giulio Cossu
Journal:  Sci Transl Med       Date:  2012-06-27       Impact factor: 17.956

Review 7.  Mechanisms and models of somatic cell reprogramming.

Authors:  Yosef Buganim; Dina A Faddah; Rudolf Jaenisch
Journal:  Nat Rev Genet       Date:  2013-06       Impact factor: 53.242

8.  Combined small-molecule inhibition accelerates developmental timing and converts human pluripotent stem cells into nociceptors.

Authors:  Stuart M Chambers; Yuchen Qi; Yvonne Mica; Gabsang Lee; Xin-Jun Zhang; Lei Niu; James Bilsland; Lishuang Cao; Edward Stevens; Paul Whiting; Song-Hai Shi; Lorenz Studer
Journal:  Nat Biotechnol       Date:  2012-07-01       Impact factor: 54.908

9.  Isolation of single-base genome-edited human iPS cells without antibiotic selection.

Authors:  Yuichiro Miyaoka; Amanda H Chan; Luke M Judge; Jennie Yoo; Miller Huang; Trieu D Nguyen; Paweena P Lizarraga; Po-Lin So; Bruce R Conklin
Journal:  Nat Methods       Date:  2014-02-09       Impact factor: 28.547

10.  Haematopoietic stem and progenitor cells from human pluripotent stem cells.

Authors:  Ryohichi Sugimura; Deepak Kumar Jha; Areum Han; Clara Soria-Valles; Edroaldo Lummertz da Rocha; Yi-Fen Lu; Jeremy A Goettel; Erik Serrao; R Grant Rowe; Mohan Malleshaiah; Irene Wong; Patricia Sousa; Ted N Zhu; Andrea Ditadi; Gordon Keller; Alan N Engelman; Scott B Snapper; Sergei Doulatov; George Q Daley
Journal:  Nature       Date:  2017-05-17       Impact factor: 49.962

View more
  3 in total

1.  Suppression of heterotopic ossification in fibrodysplasia ossificans progressiva using AAV gene delivery.

Authors:  Yeon-Suk Yang; Jung-Min Kim; Jun Xie; Sachin Chaugule; Chujiao Lin; Hong Ma; Edward Hsiao; Jaehyoung Hong; Hyonho Chun; Eileen M Shore; Frederick S Kaplan; Guangping Gao; Jae-Hyuck Shim
Journal:  Nat Commun       Date:  2022-10-19       Impact factor: 17.694

Review 2.  Contemporary perspectives on heterotopic ossification.

Authors:  Charles D Hwang; Chase A Pagani; Johanna H Nunez; Masnsen Cherief; Qizhi Qin; Mario Gomez-Salazar; Balram Kadaikal; Heeseog Kang; Ashish R Chowdary; Nicole Patel; Aaron W James; Benjamin Levi
Journal:  JCI Insight       Date:  2022-07-22

3.  ACVR1R206H extends inflammatory responses in human induced pluripotent stem cell-derived macrophages.

Authors:  Koji Matsuo; Abigail Lepinski; Robert D Chavez; Emilie Barruet; Ashley Pereira; Tania A Moody; Amy N Ton; Aditi Sharma; Judith Hellman; Kiichiro Tomoda; Mary C Nakamura; Edward C Hsiao
Journal:  Bone       Date:  2021-07-24       Impact factor: 4.398

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.